Skip to main content

Table 4 Risk factors for EGFR-TKIs induced ILD at the start of EGFR-TKIs

From: Change in serum KL-6 level from baseline is useful for predicting life-threatening EGFR-TKIs induced interstitial lung disease

Variables

 

Odds ratio

95% CI

P-value

Univariate analysis

    

   Age (years)

≥ 60/< 60

1.758

0.626-6.256

0.301

   Gender

Male/Female

1.472

0.593-3.848

0.406

   Histological type

Non-ADC/ADC

2.342

0.730-6.420

0.142

   Smoking history

Never/Smoker

1.006

0.402-2.516

0.989

   Performance status

≥ 2/0-1

0.942

0.360-2.341

0.899

   No. of prior chemotherapy regimens

≥ 2/0-1

0.800

0.277-2.053

0.652

   Prior thoracic radiotherapy

Yes/No

0.315

0.017-1.575

0.187

   Preexisting pulmonary fibrosis

Yes/No

4.683

1.741-12.042

0.003*

   Preexisting pulmonary emphysema

Yes/No

1.382

0.476-3.574

0.531

   EGFR mutation

Wild type/EGFR mutant

1.667

0.497-5.594

0.400

   Types of EGFR-TKI

Gefitinib/Erlotinib

2.043

0.562-5.948

0.253

   Serum KL-6 level at baseline (U/ml)

≥ 500/< 500

2.096

0.679-7.116

0.199

  1. *P < 0.05
  2. Abbreviation: ADC, Adenocarcinoma.